Search
Now showing items 11-20 of 34
Thiocaffeine derivatives as inhibitors of monoamine oxidase
(North-West University, 2011)
Parkinson’s disease (PD) is a neurodegenerative disorder which is characterized by selective loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc) of the brain and
reduced striatal dopamine (DA). ...
The monoamine oxidase B substrate properties of selected pyrrolinyl analogues
(North-West University, 2008)
The parkinsonian inducing agent, 1-rnethyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP), is a cyclic tertiary allylamine that is oxidized by monoamine oxidase B
(MAO-B) at the ring a-carbon to yield the 1-rnethyl-4-pheny ...
Design and synthesis of heterocyclic compounds for neuroprotective enzyme interactions
(North-West University, 2010)
Neurodegenerative diseases are thought to be multifactorial in nature and therefore
current research focus has shifted from a ‘one-drug-one-target’ approach to that of multitarget directed ligands (MTDLs). These ligands ...
Inhibition of monoamine oxidase B by substituted coumarin derivatives
(North-West University, 2008)
Interest in the selective inhibition of monoamine oxidase B (MAO-B) has increased in the last years due to their therapeutic potential in age related neurodegenerative diseases such as Alzheimer's disease and Parkinson's ...
Syntheses of chalcones and 2–aminopyrimidines and their evaluation as monoamine oxidase inhibitors and as adenosine receptor antagonists
(North-West University, 2013)
Background and rationale - Parkinson’s disease is a neurodegenerative disorder characterised by reduced levels of
dopamine in the brain. The cause of Parkinson's disease is still unknown; however several theories pertaining ...
Syntheses of sulfanylphthalimide and xanthine analogues and their evaluation as inhibitors of monoamine oxidase and as antagonists of adenosine receptors
(North-West University, 2013)
Currently L-DOPA is the drug most commonly used for the treatment of Parkinson’s disease (PD). However, the long-term use of L-DOPA is associated with the development of motor fluctuations and dyskinesias. Treatment mainly ...
Inhibition of monoamine oxidase by caffeine– and phthalide analogues
(North-West University, 2012)
Monoamine oxidase (MAO) consists of two isoforms, MAO-A and MAO-B. MAO is responsible for the oxidation of neurotransmitter and dietary amines. The MAO-B isoform, in particular, is considered to be a drug target for the ...
Synthesis and evaluation of sesamol derivatives as inhibitors of monoamine oxidase
(2014)
Parkinson’s disease is an age-related neurodegenerative disorder. The major symptoms of Parkinson’s disease are closely linked to the pathology of the disease. The main pathology of Parkinson’s disease consists of the ...
The synthesis and evaluation of phthalimide analogues as inhibitors of monoamine oxidase B
(North-West University, 2011)
Parkinson’s disease (PD) is a multifactorial neurodegenerative disease believed to be caused by a number of factors. This has made the successful treatment of the disease very difficult, as the underlying cause of degeneration ...
Novel sulfanyl– and sulfinylcaffeine analogues as inhibitors of monoamine oxidase
(North-West University, 2013)
Parkinson’s disease (PD) is a neurodegenerative disorder, which is progressive in nature and usually associated with the elderly. It is the second most common age-related neurodegenerative disorder after Alzheimer’s disease ...